1. Início
  2. Publicações
  3. Efficacy and safety of infliximab in patients with autoimmune hepatitis

Efficacy and safety of infliximab in patients with autoimmune hepatitis

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • Manuel Guilherme Gonçalves Macedo

    Autor

Participantes de fora da FMUP

  • Efe, Cumali
  • Lytvyak, Ellina
  • Eskazan, Tugce
  • Liberal, Rodrigo
  • Androutsakos, Theodoros
  • Gokce, Dilara Turan
  • Beretta-Piccoli, Benedetta Terziroli
  • Janik, Maciej
  • Bernsmeier, Christine
  • Arvaniti, Pinelopi
  • Milkiewicz, Piotr
  • Batibay, Ersin
  • Yuksekyayla, Osman
  • Ergenc, Ilkay
  • Arikan, Cigdem
  • Stattermayer, Albert F.
  • Barutcu, Sezgin
  • Cengiz, Mustafa
  • Gul, Ozlem
  • Heurgue, Alexandra
  • Heneghan, Michael A.
  • Verma, Sumita
  • Purnak, Tugrul
  • Toruner, Murat
  • Kayhan, Meral Akdogan
  • Hatemi, Ibrahim
  • Zachou, Kalliopi
  • Drenth, Joost P. H.
  • Bjornsson, Einar
  • Montano-Loza, Aldo J.
  • Wahlin, Staffan
  • Higuera-de la Tijera, Fatima

Unidades de investigação

Abstract

Background and Aims: A limited number of drugs are used as standard or alternative therapies in autoimmune hepatitis (AIH). No specific recommendations are available for patients failing to respond to these therapies. We analyzed the efficacy and safety of infliximab in patients with AIH. Approach and Results: We performed a retrospective study of 42 patients with AIH who received infliximab at 21 liver centers in 12 countries. Patients were categorized according to the reason for infliximab therapy. Patients in group 1 (n=20) had failed standard, second-line (mycophenolate mofetil and 6-mercaptopurine) or third-line (tacrolimus or cyclosporine) therapy. In group 2 (n=22), infliximab was given for treatment of concomitant extrahepatic autoimmune diseases. Patients received a median of 17 (range: 3-104) infliximab infusions. Complete biochemical response (CR) was achieved or maintained in 33 (78%) patients during infliximab therapy. In group 1, infliximab induced CR in 11 of 20 (55%) patients. In group 2, 16 patients with CR prior to infliximab maintained remission, and the remaining 6 patients with active AIH (5 on standard and 1 on both second-line and third-line therapy) showed CR following infliximab therapy. Infliximab led to CR in 75% (6/8) of nonresponders to second-line and in 46% (6/13) of failing third-line therapy. Overall, 65% (17/26) of the patients with active AIH achieved CR on infliximab. Infliximab was discontinued in 3 patients of group 1. One patient had a severe allergic reaction and 2 developed anti-infliximab autoantibodies. Conclusions: Our study suggests that infliximab may be an effective and safe rescue therapy in AIH.

Dados da publicação

ISSN/ISSNe:
0270-9139, 1527-3350

Hepatology  John Wiley and Sons Ltd

Tipo:
Article
Páginas:
-
PubMed:
39250458
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 8

Citações Recebidas na Scopus: 10

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • Liver failure; liver transplantation; rituximab; budesonide; cirrhosis; azathioprine

Campos de Estudo

Projetos associados

The contribution of endoscopic ultrasound and biomarkers in the management of pancreatic adenocarcinoma and its precursor lesions.

Investigador Principal: Manuel Guilherme Gonçalves Macedo

Estudo Clínico Académico . 2023

Noninvasive serum biomarkers of portal hypertension in liver cirrhosis

Investigador Principal: Manuel Guilherme Gonçalves Macedo

Estudo Clínico Académico . 2023

Otimização do rendimento da colangiopancreatografia retrógrada endoscópica na avaliação das estenoses pancreato-biliares indeterminadas

Investigador Principal: Manuel Guilherme Gonçalves Macedo

Estudo Clínico Académico . 2023

Endoscopic Treatment Of Upper Gastrointestinal Postsurgical Leaks

Investigador Principal: Manuel Guilherme Gonçalves Macedo

Estudo Clínico Académico . 2023

Citar a publicação

Partilhar a publicação